StockDrifts LogoStockDrifts

Pharma Research 214450

Company
파마리서치Pharma Research
Insiders
3
Buys
5
Total Value
₩412M ($286K)
Avg Return
-4.88%
Last Filing
2026-04-06

Pharma Research (214450) has 5 disclosed insider purchases and 1 disclosed disposals on record, filed by 3 distinct insiders. Together those filings cover ₩412M ($286K) in reported transaction value. The earliest filing StockDrifts holds for Pharma Research is dated 2024-10-09; the most recent is 2026-04-06. All of it is parsed from DART D001/D002 insider disclosures, the official disclosure system operated by the Financial Supervisory Service (Korea). Across these filings the average return since disclosure is -4.88%, measured from each filing date to the latest available close.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2026-04-06BUYMarket Buy
김이환
Lee Hwan Kim
Head of Financial Management Division350₩285,500+13.8%₩100M ($69K)
2026-02-12BUYMarket Buy
윤관식
Yoon Gwan-sik
Managing Director5₩348,500+2.0%₩2M ($1K)
2026-02-11BUYMarket Buy
윤관식
Yoon Gwan-sik
Managing Director75₩343,500+3.5%₩26M ($18K)
2026-01-01BUY신규선임
유용선
Yongseon Yoo
Managing Director132₩434,000-18.1%₩57M ($40K)
2025-10-30SELLMarket Sell
정래준
Raejun Jeong
Managing Director-500₩544,000+34.6%₩272M ($189K)
2025-09-22BUYMarket Buy
정래준
Raejun Jeong
Managing Director9₩609,000-41.6%₩5M ($4K)
2025-09-22BUYMarket Buy
정래준
Raejun Jeong
Managing Director11₩609,000-41.6%₩7M ($5K)
2025-03-25BUY신규선임
정래준
Raejun Jeong
Managing Director1.8K₩319,500+11.3%₩569M ($395K)
2025-03-25BUY신규선임
정래승
Jeong Rae-seung
Internal director10.0K₩319,500+11.3%₩3.2B ($2.2M)
2024-10-09BUY제3자배정유상증자
PolishCompanyLimited
major shareholders1.2M₩212,500+67.3%₩249.8B ($173.5M)

Frequently asked questions

Who has been buying Pharma Research stock?
3 distinct insiders have filed 5 disclosed insider purchases in Pharma Research (214450), most recently on 2026-04-06. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Pharma Research have?
Pharma Research has 5 buy-side and 1 sell-side disclosures on record, covering ₩412M ($286K) in total reported value, spanning 2024-10-09 to 2026-04-06.
Where does StockDrifts get Pharma Research insider data?
From DART D001/D002 insider disclosures — the official filing system run by the Financial Supervisory Service (Korea). StockDrifts parses each disclosure and matches it to daily price history; the original filings remain available directly from DART.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean DART filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

Source filings

Every trade listed above is disclosed in DART D001/D002 insider disclosures, filed with the Financial Supervisory Service (Korea). View the original DART filings for Pharma Research. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.